Medtide

Medtide Assets per Share

The Total Assets per Share of Medtide (3880.HK) as of Nov 2, 2026 is 12.78 CNY. In the previous year, Total Assets per Share was 8.27 CNY — a change of 54.57% (higher).

Assets per Share

12.78CNY

YoY

54.57%

Last updated:

Total Assets per Share of Medtide is 2025 12.78 CNY. Total Assets per Share of Medtide was 2024 8.27 CNY. It decreases by 54.57% higher compared to the previous year.

The Medtide Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2021
8.04 CNY
Jan 1, 2022
8.74 CNY
Jan 1, 2023
9.23 CNY
Jan 1, 2024
8.27 CNY
Jan 1, 2025
12.78 CNY
The Medtide Assets per Share history
YEARAssets per ShareYoY
12.78CNY+54.57%
8.27CNY-10.40%
9.23CNY+5.62%
8.74CNY+8.65%
8.04CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Total Assets per Share of Medtide is 12.78 CNY in 2025.

Total Assets per Share of Medtide changed from 8.27 CNY to 12.78 CNY, representing a 54.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Medtide since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Medtide

All Key Metrics — Medtide